$457.93
Value $247B
AMGN and NSRX stock compared: price, dividend, valuation and results, from SEC filings.
$457.93
Value $247B
$2.61
Value $24M
Amgen (AMGN) has a market value of $247B and Nasus Pharma (NSRX) $24M. Over the last year, with dividends, AMGN moved +39.7% and NSRX -64.8%. Dividend yield: AMGN 2.17%, NSRX none.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
AMGN$247B
NSRX$24M
AMGN is 10,491 times NSRX
Revenue, 12 months
AMGN$38.9B
NSRX$1.2B
AMGN is 32 times NSRX
Net income, 12 months
AMGN$9.4B
NSRX-$5.9M
Operating margin
AMGN32.4%
NSRX-0.4%
32.8 points apart
ROIC
AMGN16.2%
NSRX-140.0%
156.2 points apart
P/E
AMGN26.3
NSRX–
Dividend yield
AMGN2.2%
NSRX0.0%
2.2 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
AMGN+39.7%
NSRX-64.8%
| Period | AMGNWith dividends | NSRXWith dividends |
|---|---|---|
| 1 year since November 14, 2025 | +39.7%Price +36.0% | -64.8%Price -64.8% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
AMGNAmgenNSRXNasus Pharma
| Price | $457.93 | $2.61 |
|---|---|---|
| Market value | $247B | $24M |
| Enterprise value (EV) | $288B | $22M |
| P/E | 26.3 | – |
| P/E, 5-year median | 23.0 | – |
| P/B | 17.2 | 8.5 |
| EV/EBIT | 22.8 | – |
| Free cash flow yield | 3.9% | – |
| Revenue, 12 months | $38.9B | $1.2B |
|---|---|---|
| Net income, 12 months | $9.4B | -$5.9M |
| Free cash flow, 12 months | $9.6B | -$4.9M |
| Earnings per share, 12 months | $17.25 | -$0.72 |
| Revenue growth, year on year | 10.0% | – |
| Revenue growth a year, past | +7.6%over 5 years | – |
| EPS growth a year, past | +2.9%over 5 years | – |
| Gross margin | 70.9% | – |
|---|---|---|
| Operating margin | 32.4% | -0.4% |
| Net margin | 24.1% | -0.5% |
| ROIC | 16.2% | -140.0% |
| ROE | 87.8% | – |
| Cash | $13.2B | $1.2M |
|---|---|---|
| Total debt | $54.0B | $118.0K |
| Net debt / EBITDA | 2.3 | – |
| Interest cover | 4.8× | – |
| Dividend yield | 2.2% | – |
|---|---|---|
| Dividend per share, 12 months | $9.94 | – |
| Dividend growth a year, past | +8.1%over 5 years | – |
| Buyback yield | – | – |
| Shareholder yield | 2.2% | – |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Amgen ($247B) is about 10,491.0 times Nasus Pharma ($24M), at today's prices.
Since November 14, 2025, AMGN's price moved +36.0% and NSRX's -64.8%. With dividends: AMGN +39.7% (+39.7% a year), NSRX -64.8% (-64.8% a year). Past returns do not predict future ones.
The dividend yield at today's price is 2.17% for Amgen and none for Nasus Pharma. Over the last twelve months they paid $9.94 and – per share.
Over the last twelve months, the net margin was 24.1% for Amgen and -0.5% for Nasus Pharma, and the operating margin 32.4% and -0.4%. Revenue was $38.9B and $1.2B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.